Live Breaking News & Updates on Monique Gore Massy

Stay updated with breaking news from Monique gore massy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Rheumatology Summit Tackles Race Disparities in Lupus Trials

Researchers and patients explore why so few Black individuals sign up for studies and highlight projects that aim to develop better strategies. ....

New York , United States , Richardae Araojo , Shanelle Gabriel , Pamela Payne Foster , Saira Sheikh , Aleta Mclean , Stacey Kennedy Conner , Monique Gore Massy , Diversity In Lupus Research Program , American College Of Rheumatology , Community Engagement , Health Equity , Office Of Minority Health , Lupus Foundation Of America , University Of Alabama , University Of North Carolina At Chapel Hill , Lupus Research Alliance , Joy Buie , Diverse Participants , Lupus Clinical Trials , American College , African American , New York City , Increase Minority Enrollment , North Carolina ,

Monique Gore-Massy

Monique Gore-Massy ....

United States , Monique Gore Massy , Lupus Foundation Of America , American College Of Rheumatology , Lupus Foundation , American College ,

Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis

Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis
First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus
News provided by
Share this article
Share this article
WASHINGTON, Jan. 22, 2021 /PRNewswire/ For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-related kidney disease) in combination with a background immunosuppressive therapy regimen. Today, Aurinia Pharmaceuticals announced they received authorization from the FDA to market Lupkynis™ (voclosporin), a first-ever oral therapy for lupus nephritis that blocks a protein in the immune system called calcineurin. The company previously had reported positive data from a late- ....

United States , Susanm Manzi , Monique Gore Massy , Karenh Costenbader , Stevanw Gibson , Mike Donnelly , Lupus Foundation Of America Ambassador , Drug Administration , Allegheny Health Network Medicine Institute , Scientific Advisory Council , Lupus Program At Brigham , Aurinia Pharmaceuticals , Lupus Foundation Of America , Lupus Center , Lupus Foundation , Board Chair , Medical Director , Lupus Program , Medical Scientific Advisory Council , Research Accelerated , ஒன்றுபட்டது மாநிலங்களில் , மொநீக் கார் வெகுஜன , மைக் டோநிலீ , லூபஸ் அடித்தளம் ஆஃப் அமெரிக்கா தூதர் , அல்லேஜிஹினி ஆரோக்கியம் வலைப்பின்னல் மருந்து நிறுவனம் , லூபஸ் ப்ரோக்ர்யாம் இல் ப்ரிகாம் ,